Aspartate Aminotransferase-to-Platelet Ratio Index (APRi) as Biomarker for Liver Damage in Biliary Atresia (BA): A Meta-analysis

In brief

This correspondence addresses diagnostic accuracy considerations for using the APRI score as a non-invasive biomarker to assess liver damage in pediatric patients with biliary atresia. The authors respond to critiques of their meta-analysis examining APRI's clinical utility in this rare cholestatic liver disease.

• APRi shows promise as a non-invasive biomarker for assessing liver damage severity in biliary atresia patients.
• Meta-analysis synthesizes evidence on APRi's diagnostic performance, informing clinical decision-making in BA management.
• Authors engage with peer critique on diagnostic accuracy metrics, refining interpretation of APRi utility in pediatric hepatology.

Written by the GCMD Library team from the article.